Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 2/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.37 |
| ▸ | CCND1 | P24385 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL49276 | 0.98 | CCNB2 (0.36) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL12441277 | 0.83 | CCNB2 (0.38) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL12825994 | 0.83 | — | — | |
| SCHEMBL3265214 | 0.81 | — | — | |
| SCHEMBL2074090 | 0.80 | CCNB2 (0.37) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL5539198 | 0.80 | CCNB2 (0.37) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL19668056 | 0.79 | PRMT6 (0.39) | HRH1HRH4LOXL2 | |
| SCHEMBL5537266 | 0.77 | CCNB2 (0.35) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL17371372 | 0.76 | CCNB2 (0.40) | CCNB2CCNE2CDK1CDK4CCNB1 | |
| SCHEMBL5543606 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| CN-101970420-B | Oxadiazole derivatives | MERCK SERONO SA | 2014-09-24 | — | — | CN | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | disclosed |
| US-8354418-B2 | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-8354418-B2 | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-8354418-B2 | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| CN-1838953-A | Phosphatidylinositol 3-kinase (PI3) inhibitor 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives for the treatment of inflammatory airway diseases | NOVARTIS AG (CH) | 2006-09-27 | — | — | CN | disclosed |
| EP-1689391-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| CN-1816549-A | Phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| CN-1639139-A | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | NOVARTIS AG (CH) | 2005-06-02 | — | — | US | disclosed |
| WO-2005021519-A2 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY AIRWAY DISEASES | NOVARTIS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| EP-1480962-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | Novartis AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2003072557-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119320-A1 | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors | PIK3CA, PIK3R5, PIP5K1B | CCNB2 826/4885CCNE2 343/4885CDK1 69/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | CCNB2 865/4885CCNE2 967/4885CDK1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.